Cargando…

Australian Parkinson’s Genetics Study (APGS): pilot (n=1532)

PURPOSE: Parkinson’s disease (PD) is a neurodegenerative disorder associated with progressive disability. While the precise aetiology is unknown, there is evidence of significant genetic and environmental influences on individual risk. The Australian Parkinson’s Genetics Study seeks to study genetic...

Descripción completa

Detalles Bibliográficos
Autores principales: Bivol, Svetlana, Mellick, George D, Gratten, Jacob, Parker, Richard, Mulcahy, Aoibhe, Mosley, Philip E, Poortvliet, Peter C, Campos, Adrian I, Mitchell, Brittany L, Garcia-Marin, Luis M, Cross, Simone, Ferguson, Mary, Lind, Penelope A, Loesch, Danuta Z, Visscher, Peter M, Medland, Sarah E, Scherzer, Clemens R, Martin, Nicholas G, Rentería, Miguel E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883215/
https://www.ncbi.nlm.nih.gov/pubmed/35217535
http://dx.doi.org/10.1136/bmjopen-2021-052032
_version_ 1784659874275131392
author Bivol, Svetlana
Mellick, George D
Gratten, Jacob
Parker, Richard
Mulcahy, Aoibhe
Mosley, Philip E
Poortvliet, Peter C
Campos, Adrian I
Mitchell, Brittany L
Garcia-Marin, Luis M
Cross, Simone
Ferguson, Mary
Lind, Penelope A
Loesch, Danuta Z
Visscher, Peter M
Medland, Sarah E
Scherzer, Clemens R
Martin, Nicholas G
Rentería, Miguel E
author_facet Bivol, Svetlana
Mellick, George D
Gratten, Jacob
Parker, Richard
Mulcahy, Aoibhe
Mosley, Philip E
Poortvliet, Peter C
Campos, Adrian I
Mitchell, Brittany L
Garcia-Marin, Luis M
Cross, Simone
Ferguson, Mary
Lind, Penelope A
Loesch, Danuta Z
Visscher, Peter M
Medland, Sarah E
Scherzer, Clemens R
Martin, Nicholas G
Rentería, Miguel E
author_sort Bivol, Svetlana
collection PubMed
description PURPOSE: Parkinson’s disease (PD) is a neurodegenerative disorder associated with progressive disability. While the precise aetiology is unknown, there is evidence of significant genetic and environmental influences on individual risk. The Australian Parkinson’s Genetics Study seeks to study genetic and patient-reported data from a large cohort of individuals with PD in Australia to understand the sociodemographic, genetic and environmental basis of PD susceptibility, symptoms and progression. PARTICIPANTS: In the pilot phase reported here, 1819 participants were recruited through assisted mailouts facilitated by Services Australia based on having three or more prescriptions for anti-PD medications in their Pharmaceutical Benefits Scheme records. The average age at the time of the questionnaire was 64±6 years. We collected patient-reported information and sociodemographic variables via an online (93% of the cohort) or paper-based (7%) questionnaire. One thousand five hundred and thirty-two participants (84.2%) met all inclusion criteria, and 1499 provided a DNA sample via traditional post. FINDINGS TO DATE: 65% of participants were men, and 92% identified as being of European descent. A previous traumatic brain injury was reported by 16% of participants and was correlated with a younger age of symptom onset. At the time of the questionnaire, constipation (36% of participants), depression (34%), anxiety (17%), melanoma (16%) and diabetes (10%) were the most reported comorbid conditions. FUTURE PLANS: We plan to recruit sex-matched and age-matched unaffected controls, genotype all participants and collect non-motor symptoms and cognitive function data. Future work will explore the role of genetic and environmental factors in the aetiology of PD susceptibility, onset, symptoms, and progression, including as part of international PD research consortia.
format Online
Article
Text
id pubmed-8883215
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-88832152022-03-17 Australian Parkinson’s Genetics Study (APGS): pilot (n=1532) Bivol, Svetlana Mellick, George D Gratten, Jacob Parker, Richard Mulcahy, Aoibhe Mosley, Philip E Poortvliet, Peter C Campos, Adrian I Mitchell, Brittany L Garcia-Marin, Luis M Cross, Simone Ferguson, Mary Lind, Penelope A Loesch, Danuta Z Visscher, Peter M Medland, Sarah E Scherzer, Clemens R Martin, Nicholas G Rentería, Miguel E BMJ Open Neurology PURPOSE: Parkinson’s disease (PD) is a neurodegenerative disorder associated with progressive disability. While the precise aetiology is unknown, there is evidence of significant genetic and environmental influences on individual risk. The Australian Parkinson’s Genetics Study seeks to study genetic and patient-reported data from a large cohort of individuals with PD in Australia to understand the sociodemographic, genetic and environmental basis of PD susceptibility, symptoms and progression. PARTICIPANTS: In the pilot phase reported here, 1819 participants were recruited through assisted mailouts facilitated by Services Australia based on having three or more prescriptions for anti-PD medications in their Pharmaceutical Benefits Scheme records. The average age at the time of the questionnaire was 64±6 years. We collected patient-reported information and sociodemographic variables via an online (93% of the cohort) or paper-based (7%) questionnaire. One thousand five hundred and thirty-two participants (84.2%) met all inclusion criteria, and 1499 provided a DNA sample via traditional post. FINDINGS TO DATE: 65% of participants were men, and 92% identified as being of European descent. A previous traumatic brain injury was reported by 16% of participants and was correlated with a younger age of symptom onset. At the time of the questionnaire, constipation (36% of participants), depression (34%), anxiety (17%), melanoma (16%) and diabetes (10%) were the most reported comorbid conditions. FUTURE PLANS: We plan to recruit sex-matched and age-matched unaffected controls, genotype all participants and collect non-motor symptoms and cognitive function data. Future work will explore the role of genetic and environmental factors in the aetiology of PD susceptibility, onset, symptoms, and progression, including as part of international PD research consortia. BMJ Publishing Group 2022-02-25 /pmc/articles/PMC8883215/ /pubmed/35217535 http://dx.doi.org/10.1136/bmjopen-2021-052032 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Neurology
Bivol, Svetlana
Mellick, George D
Gratten, Jacob
Parker, Richard
Mulcahy, Aoibhe
Mosley, Philip E
Poortvliet, Peter C
Campos, Adrian I
Mitchell, Brittany L
Garcia-Marin, Luis M
Cross, Simone
Ferguson, Mary
Lind, Penelope A
Loesch, Danuta Z
Visscher, Peter M
Medland, Sarah E
Scherzer, Clemens R
Martin, Nicholas G
Rentería, Miguel E
Australian Parkinson’s Genetics Study (APGS): pilot (n=1532)
title Australian Parkinson’s Genetics Study (APGS): pilot (n=1532)
title_full Australian Parkinson’s Genetics Study (APGS): pilot (n=1532)
title_fullStr Australian Parkinson’s Genetics Study (APGS): pilot (n=1532)
title_full_unstemmed Australian Parkinson’s Genetics Study (APGS): pilot (n=1532)
title_short Australian Parkinson’s Genetics Study (APGS): pilot (n=1532)
title_sort australian parkinson’s genetics study (apgs): pilot (n=1532)
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883215/
https://www.ncbi.nlm.nih.gov/pubmed/35217535
http://dx.doi.org/10.1136/bmjopen-2021-052032
work_keys_str_mv AT bivolsvetlana australianparkinsonsgeneticsstudyapgspilotn1532
AT mellickgeorged australianparkinsonsgeneticsstudyapgspilotn1532
AT grattenjacob australianparkinsonsgeneticsstudyapgspilotn1532
AT parkerrichard australianparkinsonsgeneticsstudyapgspilotn1532
AT mulcahyaoibhe australianparkinsonsgeneticsstudyapgspilotn1532
AT mosleyphilipe australianparkinsonsgeneticsstudyapgspilotn1532
AT poortvlietpeterc australianparkinsonsgeneticsstudyapgspilotn1532
AT camposadriani australianparkinsonsgeneticsstudyapgspilotn1532
AT mitchellbrittanyl australianparkinsonsgeneticsstudyapgspilotn1532
AT garciamarinluism australianparkinsonsgeneticsstudyapgspilotn1532
AT crosssimone australianparkinsonsgeneticsstudyapgspilotn1532
AT fergusonmary australianparkinsonsgeneticsstudyapgspilotn1532
AT lindpenelopea australianparkinsonsgeneticsstudyapgspilotn1532
AT loeschdanutaz australianparkinsonsgeneticsstudyapgspilotn1532
AT visscherpeterm australianparkinsonsgeneticsstudyapgspilotn1532
AT medlandsarahe australianparkinsonsgeneticsstudyapgspilotn1532
AT scherzerclemensr australianparkinsonsgeneticsstudyapgspilotn1532
AT martinnicholasg australianparkinsonsgeneticsstudyapgspilotn1532
AT renteriamiguele australianparkinsonsgeneticsstudyapgspilotn1532